Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Iowa Approach

Request full access

Growing Innovation & transforming the practice of medicine

Menlo Park, United StatesFounded 2012Biotech & Life Sciences

About Iowa Approach

Iowa Approach Inc., which was subsequently rebranded as Farapulse, Inc., represents a significant development in the field of cardiac electrophysiology. The company was established in 2012 by Dr. Steven Mickelsen, an assistant professor and clinical cardiac electrophysiologist at the University of Iowa. Drawing on more than a decade of direct experience within cardiac catheterization labs, Dr. Mickelsen identified critical limitations in existing treatments for atrial fibrillation (AFib), the world's most common heart rhythm disorder. This firsthand insight drove him to invent and prototype a novel medical device system to make AFib ablation safer, faster, and more accessible.

The company's core business revolves around its Pulsed Field Ablation (PFA) system. This technology addresses a market where an estimated 59 million people globally suffer from AFib, a condition that increases the risk of stroke and carries a significant healthcare cost burden. The business model focused on the development and commercialization of this proprietary medical device. Unlike traditional thermal ablation methods that use extreme heat or cold to destroy problematic heart tissue and risk damaging surrounding structures, the Farapulse PFA system utilizes non-thermal, tissue-selective electric fields. This method allows for the precise ablation of cardiac tissue responsible for irregular heartbeats while preserving adjacent healthy tissue, such as the esophagus or phrenic nerve. The primary clients for this technology are hospitals and cardiac electrophysiologists who perform ablation procedures.

The Farapulse system, consisting of a specialized catheter and an energy generator, demonstrated a substantial improvement in safety and procedural efficiency. Clinical data and real-world use have shown a high rate of effectiveness with no reported instances of common complications like esophageal injury or pulmonary vein stenosis. The journey from concept to market was supported by the University of Iowa Research Foundation, and the company attracted early investment from Boston Scientific in 2014. This strategic relationship culminated in June 2021, when Boston Scientific exercised its option to fully acquire Farapulse, Inc. The acquisition involved an upfront payment of approximately $295 million for the remaining stake, plus potential milestone and revenue-based payments. The system received FDA approval for treating paroxysmal AFib in January 2024 and expanded approval for persistent AFib in July 2025, solidifying its position within the Boston Scientific electrophysiology portfolio.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2012
Headquarters
Menlo Park, United States
Employees
7
Open positions
None listed
Dealroom signal
59.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Aug 2018 $12M $48M Undisclosed —
DEBT✓Debt Jul 2017 $5M — Undisclosed —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Iowa Approach website traffic

Latest recorded traffic for Iowa Approach is 110 monthly website visits. Iowa Approach's team declined 22.2% over the past year.

Latest monthly visits110 1-year team growth-22.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Iowa Approach in the Menlo Park ecosystem

Live from Dealroom

The Iowa Approach office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Sante Ventures

Other known investors1 additional known investor

  • University of Iowa
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States75%
🇨🇿 Czech Republic25%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Iowa Approach on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Iowa Approach’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.